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Obesity is associated with an increased risk of breast cancer. interleukin-1 (IL-1), a pro-inﬂamma-
tory cytokine secreted by adipose tissue, is involved in breast cancer development. There is also con-
vincing evidence that other adipocytokines including leptin not only have a role in haematopoiesis,
reproduction and immunity but are also growth factors in cancer. Therefore, IL-1 family and leptin
family are adipocytokines which could represent a major link between obesity and breast cancer
progression. This minireview provides insight into recent ﬁndings on the prognostic signiﬁcance
of IL-1 and leptin in mammary tumours, and discusses the potential interplay between IL-1 family
members and adipocyte-derived hormones in breast cancer.
 2008 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction as a factor in tumour progression via the expression of metastaticRecent epidemiological andmolecular evidenceshaveestablished
obesity as a risk factor for breast cancer incidence (post-menopausal)
and morbidity [1]. One of the mechanisms that might explain the
relationship betweenobesity and hormone-dependent breast cancer
development is estrogen overproduction by adipose tissue derived
from elevated androgen aromatization. However, themammary adi-
pose tissue is also an important source of angiogenic factors, para-
crine mitogens and anti-mitogens, including growth factors and
‘‘adipocytokines”. This last termcomprises adipokines (leptin, adipo-
nectin, visfatin, and resistin) and numerous pro-inﬂammatory cyto-
kines secreted by adipocytes and involved in the mediation or
coordination of inﬂammatory diseases and obesity [2].
Many reviews have addressed the role of IL-6, TNF-a and MCP-1
as adipocytokines in the pathophysiology of inﬂammatory pro-
cesses with respect to breast cancer [3,4], but little attention has
been paid to IL-1 family members.
Interleukin-1 (IL-1), one of the major pro-inﬂammatory cyto-
kines, is increased in patients with cancers [5]. IL-1 is known to
be upregulated in many tumour types and has been implicatedchemical Societies. Published by E
ukin-1 receptor antagonist;
n receptor; BMI, body mass
.and angiogenic genes, and growth factors. A number of studies
have reported that high IL-1 concentrations within the tumour
microenvironment are associated with a more virulent tumour
phenotype. For example, solid tumours in which IL-1 has been
shown to be upregulated include melanomas, colon, lung, head
and neck cancers, and patients with high IL-1 producing tumours
have generally bad prognoses [6–9].
Members of IL-1 family are adipocytokines since they have been
well documented not only in breast cancer cells in vitro [10] as
well as in vivo [11] but also in human adipose tissue which pro-
duces 5- to 10-fold more IL-1 family cytokines than TNF and IL-6
[12].
In breast biopsies, IL-1 is one of the 5 cytokines (along with IL-2,
IL-4, IL-10 and G-CSF, most of themmediating IL-1 biological activ-
ities) not detected in normal breast and overexpressed in breast
carcinoma [13].
IL-1 may not be the only adipocytokine associated with breast
cancer but it is considered as an upstream ‘‘alarm” adipocytokine
since its production (even in small amounts) induces potent sec-
ondary responses, in part through its ability to elicit secretion of
other cytokines, chemokines, adhesion molecules and receptors
for cytokines from diverse cells [5]. Indeed, according to Lewis
et al. [14], IL-1 plays an early role in tumour growth and metastasis
since in the tumour microenvironment, secreted IL-1 has
local effects on other cells (endothelial cells, stromal cells, andlsevier B.V. All rights reserved.
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tion factors (NF-kappaB, AP-1), adhesion molecules, proangiogenic
and prometastatic mediators such as VEGF, IL-6, IL-8, matrix
metalloproteinases (MMPs), macrophage-inﬂammatory protein-1
(MIP-1) and bFGF. Therefore, IL-1 is an upstream signal that initi-
ates the production of other mediators in cancer and recent studies
have determined the necessity of IL-1 in tumour growth and inva-
siveness, and angiogenesis [15].
Leptin is secreted mainly by adipocytes. However, leptin expres-
sion has been observed in non-adipocytes cells like breast cancer cell
lines, and this expression can be modulated by IL-1 [16–18]. The pri-
mary role of IL-1 in the induction of leptin during inﬂammation [16]
suggests that some of the biological activities of IL-1 may be speciﬁ-
cally mediated by leptin. Moreover, recent data demonstrate a genu-
ine interplay (ie a mutual regulation) between leptin and IL-1 family
members in different models including breast cancer [19–21]. We
have recently reported such an interplay in metabolic diseases and
obesity [22] and it may also occur in breast cancer.
Therefore, it was important to review for the ﬁrst time the re-
cent advances regarding the action of IL-1 members as adipocyto-
kines in breast cancer, with a special focus on their interactions
with other adipocytokines, in particular leptin.2. IL-1 family: generalities
IL-1 family is mainly represented by pro-inﬂammatory cyto-
kines IL-1a and IL-1b, interleukin-1 receptor antagonist (IL-1ra)
and their receptors.
There are mainly two cell-surface IL-1 receptors: IL-1RI (type I
receptor) and IL-1RII (type II receptor) but the type I receptor, an
80-kDa protein with a cytoplasmic domain of approximately 215
amino acids, is the only receptor responsible for IL-1 signaling.
The type II receptor, a 60-kDa protein with a truncated cytoplasmic
domain of 29 amino acids, binds IL-1 and thereby prevents it from
binding to the type I receptor but does not deliver a biological sig-
nal. The type II receptor is then considered as a ‘‘decoy” receptor.
IL-1a and IL-1b bind to the type I receptor with the same afﬁnity.
IL-1ra also binds to type I receptor and type II receptor with nearly
the same afﬁnity as IL-1a and IL-1b and yet does not trigger a
response, antagonizing competitively the inﬂammatory effects of
IL-1 [for a review, see [5]]. Thus IL-1ra is a naturally occurring
inhibitor, which is unique in the cytokine world. An excess of
IL-1ra is necessary to counteract the effects of IL-1 in vitro. This
excess reaches 1000 in breast cancer tissue homogenates [11].
Since IL-1ra does not induce signal transduction, the ‘‘activity’’
of IL-1ra is regulated only by its levels of production which are con-
trolled by regulatory molecules (inhibitors and enhancers). A
deregulation in the balance between IL-1 and IL-1ra is one of the
factors inﬂuencing the course, the susceptibility to and the severity
of many diseases [23]. In the past few years, IL-1ra has attracted
considerable clinical attention because its serum levels are ele-
vated in pathologies as diverse as sepsis, cancer, metabolic diseases
and auto-immune diseases [24] whereas the plasma IL-1ra/IL-1 ra-
tio in a healthy population is close to 1 and exhibits minimal var-
iation [25]. A signiﬁcant increase of plasma IL-1ra is associated
with post-treatment fatigue in breast cancer survivors [26].
The increase in circulating IL-1ra levels corresponds to a de-
layed event in response to IL-1 production and may represent a
preventive mechanism in long-acting and/or excessive inﬂamma-
tory response. In contrast, the inﬂammatory site is more likely
unbalanced in favor of IL-1, especially in severe lesions [27] and
insufﬁcient production of endogenous IL-1ra may contribute to
the pathogeny of these conditions [see [22] for more details].
Recombinant IL-1 receptor antagonist (recIL-1ra or anakinra) is
an anti-inﬂammatory protein routinely used as a therapeutic mol-ecule in rheumatoid arthritis [28] in subcutaneous daily injections
(20–200 mg) with relatively few side effects, mainly local inﬂam-
matory reactions at the injection site. As documented by Arend
[23], recIL-1ra clinical trials have been also conducted in different
diseases like sepsis and graft versus host disease. Anakinra is well
absorbed in humans and its safety is well documented with few
adverse reactions, making it an ideal candidate in the adjuvant
therapy in cancers. More recently, Larsen et al. [29] discussed the
possibility of using anakinra for treatment of type 2 diabetes while
Ricci et al. reported that local delivery of IL-1ra in colon mucosa
through genetically engineered sporulating bacteria successfully
reduced disease progression in a murine model of ulcerative colitis
[30].
RecIL-1ra drug development has been also reported at a pre-
clinical stage in murine models of melanoma [31] and ﬁbrosar-
coma [32] where sustained IL-1ra was delivered in vivo from bio-
degradable microspheres. Additionally, IL-1ra blocked IL-1 induced
production of colony-stimulating growth factors (CSF) by ﬁbro-
blasts, lymphocytes and monocytes in acute and chronic myeloge-
nous leukemias [33,34]. All these data conﬁrm that recombinant
IL-1 receptor antagonist is a potential drug in cancer treatment
[14]. Current clinical trials in breast cancer include other cytokines
alone or in combination with other drugs [35].3. IL-1 family and breast cancer
Normal human mammary epithelial cells (HMEC) express the
receptors for IL-1 family members since IL-1b inhibits signiﬁcantly
the proliferation of HMECs and IL-1ra blocks this growth inhibition
[36]. Both expression and distribution of IL-1 family members have
been well studied in human mammary cancer tissue where they
regulate tumour activity within the microenvironment surround-
ing breast tumour [37–39]. IL-1 levels are signiﬁcantly increased
in ductal invasive tissues as compared in benign tissues [11] and
elevated levels of IL-1b are correlated with invasiveness and
aggressiveness of breast cancer [37] and with a high tumour grade
[13]. In addition to proliferation, IL-1 has been linked to invasion,
angiogenesis and inhibition of apoptosis in cancer cells [14,15].
IL-1 family members also modulate the hormone activity of
estrogens and their receptors. Indeed, IL-1 expression is observed
mostly in estrogen receptor negative breast cancers, which are
usually more invasive and metastatic and associated with poor
prognosis [39]. It has been shown that breast cancer cell prolifera-
tion induced by IL-1 is mediated by P450 aromatase and steroid
sulfatase (STS), two estrogen-producing enzymes [40]. Aromatase
activity that converts androgens to estrogens has been identiﬁed
in 50-60% of breast cancers whereas STS converts conjugate estro-
gens to free potent estrogens and is found in almost all types of
breast cancer [41]. Honma et al. [40] have reported that when IL-
1b (10 ng/ml) is added to the medium of SK-BR3 breast cancer cell
line, the amount of aromatase activity is signiﬁcantly enhanced to
120% of the control. In MCF-7 cells, the level of STS activity was
also signiﬁcantly enhanced to 130% of the control by IL-1b and this
enhanced activity was completely reversed by the addition of
IL-1ra (100 ng/ml) in the medium. In these cells, IL-1b also signif-
icantly increased cell proliferation in the presence of E1-S (STS-
inhibitor). All together, these data suggest that increased IL-1
levels in breast cancer tissue enhance the proliferation of cancer
cells through stimulating the activity of steroid catalyzing enzymes
such as STS and aromatase that produce bioactive estrogens.
Moreover, IL-1 down-regulates expression of estrogen receptors
in mammary cancer cell lines [42,43], leading to estrogen bioavail-
ability whereas IL-1ra levels are directly correlated with those of
estrogen receptors [39]. High IL-1ra levels and low IL-1 levels at
the tumour site are associated with a good prognosis of breast can-
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[11]. In a more recent work, high circulating IL-1ra concentrations
represent a prognostic factor in breast cancer patients over 50
years old, especially when tumour cells lack of estrogen receptors
[44]. IL-1 receptors are expressed in estrogen-dependent (MCF-7,
ZR75-1) as well as in estrogen-independent cell lines (MDA-MB
231) [11]. In contrast, genes of IL-1a, IL-1b, and IL-1ra are preferen-
tially expressed in highly malignant and invasive mammary cell
lines (BT 20, BT 549, HS 578T, and MDA-MB 231) and are not de-
tected in other cell lines tested (MCF-7, T47-D, ZR75-1, and
SKBR-3) [10]. In one study, however, the authors found no IL-1b
expression in the three breast cancer cell lines MCF-7, MDA-
MB231 and MDA-MB468 [36]. Collectively, this body of work sug-
gests an autocrine/paracrine functional IL-1 system in the model of
breast cancer.
A Korean study showed that a rare polymorphism of IL-1ra gene
(IL-1RN*2) reduces the risk of breast cancer, especially when asso-
ciated with a low body mass index (BMI) [45], suggesting that a ge-
netic aspect of IL-1 may inﬂuence the susceptibility to tumour
development. Further studies will be necessary to clarify the role
of this polymorphism in breast cancer, especially its inﬂuence on
systemic and local production of IL-1ra since we have previously
found that IL-1RN*2 allele accentuates the differential IL-1ra
expression in blood and at the inﬂammatory site [46].4. Leptin and breast cancer
Another mechanism explaining the association between obesity
and breast cancer implicates leptin, which is now considered as a
pro-inﬂammatory adipocytokine [47].
Numerous studies have demonstrated that leptin stimulates the
proliferation of breast cancer cell lines [48–51]. The presence of
leptin and its receptor (ObR) has been described in vitro in the nor-
mal human breast epithelial cell line MCF10A [17] and HBL100
[49] respectively, as well as in breast cancer cell lines [17,49,52].
We have recently investigated leptin and ObR expression in vivo
in epithelial or ductal tissues of breast tumours [53–55]. We have
identiﬁed leptin as a proliferative factor in human breast carci-
noma since immunohistochemical expression of leptin on biopsies
correlates with the different stages of tumour invasion in ductal
tissues [54,55]. In addition, leptin is not expressed in healthy
breast tissue [54] but is detected in normal tissue adjacent to duc-
tal carcinoma, suggesting leptin may be a prognostic marker of
early tumourigenicity in human ductal breast carcinoma.
We have also detected the presence of leptin receptor (ObR) in
human breast carcinoma but not in normal breast tissue [53].
These data are consistent with another study in which an immuno-
histochemical staining failed to reveal the presence of ObR in nor-
mal mammary epithelium [56]. ObR expression was investigated
by immunohistochemical staining from tissue sections of invasive
breast carcinomas and varied from 75–83% [55,56] to 41% [57]
depending on the study.
Enhanced expression of ObR in tumours simultaneously with
high levels of circulating leptin in serum is a risk factor and may
explain the association between obesity and breast cancer [58].
Both leptin and ObR expressions are more abundant in tumours
with a high grade [57]. Interestingly, leptin and ObR are co-ex-
pressed in primary breast carcinoma, suggesting that leptin acts
on mammary tumour cells via an autocrine pathway [55].
Finally, leptin is able to induce the aromatase gene expression
in MCF-7 cells through an enhanced binding of AP-1 to speciﬁc
DNA sites in the promoter region [59]. AP-1 transcription factors
are known to regulate the expression of many cytokines. AP-1
are more abundant in estrogen receptor negative breast tumour
samples than in estrogen receptor positive ones [60]. Interestingly,Chavey et al. [13] showed that in breast cancer, high AP-1 levels
correlated with high levels of expression of several cytokines,
including IL-1b. Moreover, leptin derived from breast and abdom-
inal adipose tissue of obese women increases aromatase activity
and is a potential stimulator of estrogen synthesis that favored
growth of breast glandular epithelium [61]. The fact that ObR
expression positively correlates with estrogen receptor and tu-
mour size [55] points to a possible interaction between leptin
and estrogen systems to promote breast carcinogenesis and con-
ﬁrms the potential role of leptin as a growth factor.
5. Interaction between IL-1 family and leptin
Since the discovery of leptin as an adipocytokine, many other
metabolic activities have been demonstrated, leptin interfering
with fetal development, haematopoiesis, reproduction and immu-
nity [see [62] for a review]. Although leptin is not a classical cyto-
kine, several immune cells (such as polymorphonuclear leukocytes,
monocytes, macrophages and lymphocytes) bear ObRs and their
activity can be modulated by leptin [63–67]. For example, leptin
increases macrophage activation and cytokine release [62].
The expression of both leptin and IL-1 families has been shown
to be associated in several pathological situations [19–21,68], sug-
gesting an interplay between them. We have recently reported an
interplay between IL-1 family and leptin in metabolic diseases and
obesity [22] but the simultaneous production of both these adipo-
cytokines has never been described in human breast cancer. In a
murine model of breast cancer, MCF-7 cells produce a high amount
of IL-1a, which in turn induces leptin expression in stromal cells or
in inﬁltrating immune cells recruited in tumour microenvironne-
ment [19]. In rats, elevated concentrations of IL-1b in peripheral
blood increase leptin levels concomitantly with the total body fat
mass, and stimulate growth of mammary epithelium [69].
Recent work has demonstrated that leptin regulates IL-1 family
members in a diabetic context [70]. Leptin decreases b-cell produc-
tion of IL-1ra and induces IL-1b release. IL-1ra modulation by lep-
tin is cell-speciﬁc since leptin induces IL-1ra expression in
monocytes [71] and in macrophages [72], suggesting an anti-
inﬂammatory role of leptin in these cells. Lower IL-1ra levels are
also detected in serum of leptin-deﬁcient mice deﬁcient ob/ob
after stimulation with LPS [72]. In HepG2 and THP-1 cells, the acti-
vation of the IL-1ra promoter by leptin involves the activation of
MAP kinase and the binding of a yet uncharacterized factor to
the nuclear factor kappa B binding site of the IL-1ra promoter
[73]. Other works have shown leptin synthesis by human preadi-
pocytes is stimulated in a paracrine manner by IL-1b and TNFa
(which are secreted by macrophages inﬁltrating adipose tissue)
[74]. IL-1b is a mediator of inﬂammatory effects of leptin since lep-
tin production induced during local and systemic inﬂammation is
observed in IL-1b+/+ mice but not in IL-1b/ mice [16].
As it is recognized that leptin acts both at the central nervous
system and at the peripheral level, it may also exert its effects in
morbid obesity through the IL-1 pathway and IL-1ra may contrib-
ute to central leptin resistance by inhibiting the leptin-induced
reduction in food intake [75].6. Interaction between IL-1 family and other adipocytokines
The interplay between the different adipocytokines plays a key
role in the development of obesity-related cancers like breast can-
cers [3,76].
We have recently explored simultaneously the expression of
leptin and adiponectin both in breast cancer cell lines and in
mammary tissue of ductal carcinoma [77,78] and suggested antag-
onistic properties of these two adipocytokines in breast cancer
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adiponectin in human breast cancer cell growth via activation of
cell apoptosis and inhibition of cell cycle [79,80], suggesting that
adiponectin could act in vivo as a paracrine/endocrine growth
inhibitor towards mammary epithelial cells.
To date, only one study has explored the simultaneous levels of
leptin, adiponectin and resistin in serum of breast cancer patients
[81] and few studies have addressed the interplay between IL-1
members and other adipocytokines. IL-1 has been described to
abolish completely adiponectin secretion in adipocytes [74] while
IL-1ra induction by adiponectin has been reported in human leuko-
cytes [82]. A low serum level of adiponectin is generally considered
as a risk factor in the breast cancer development among post-men-
opausal, but not pre-menopausal women [81,83]. Similarly, low
circulating levels of IL-1ra may be indicator of a good prognosis
since in healthy population, individuals with low serum IL-1ra con-
centrations have higher levels of adiponectin [84]. However, aTable 1
Summary of the association of IL-1 family members (a), leptin and adiponectin family (b) wi
cancer cell lines; ER: estrogen receptor; IDC: invasive ductal carcinoma; ILC: invasive lobu
Adipocytokine Location Effect
(a)
IL-1a Tissue Negative correlati
Tissue Increase in DCIS o
Tissue Positive correlatio
CL Genes expressed
CL Down-regulates e
Tissue Positive correlatio
IL-1b Tissue Increase in DCIS o
Tissue Positive correlatio
Tissue Positive correlatio
Tissue Increase in invasi
Tissue Increase in invasi
Tissue Negative correlati
Tissue Negative correlati
Tissue Positive correlatio
CL Enhances aromata
CL Genes expressed
IL-1ra Tissue Positive correlatio
Plasma Increase in BC sur
Tissue Increase in IDC vs
Serum High levels in pat
CL Genes expressed
IL-1/IL-1ra Tissue Positive associatio
IL-1RI and II Tissue Increase in DCIS o
(b)
Leptin CL Proliferative effec
Tissue Positivity in 80% I
Tissue Positivity in 86% o
CL Enhances aromata
Tissue Positive correlatio
Tissue Positive correlatio
Serum High levels associ
Serum Positive correlatio
CL Regulates epitheli
ObR Tissue Positivity in 75% o
Tissue Positivity in 83% o
Tissue Positivity in 41% o
Tissue Increase in BC vs.
Tissue Positive correlatio
Tissue Positive correlatio
Tissue High levels associ
Adiponectin Serum Low levels associa
Tissue High levels associ
Tissue Positivity in 15% I
CL Anti-proliferative
Adipo-R CL Expressed in BC
Resistin Serum High levels associdichotomy may exist between circulating and tissue levels of
adiponectin since high tissue adiponectin levels are more likely
associated with increased risk for breast cancer [85]. We have pre-
viously found such a dichotomy between the systemic production
of IL-1ra and its local production at the inﬂammatory site, and sug-
gested separate regulatory mechanisms in different compartments
[46].
7. Conclusion
Leptin and IL-1 family members are «adipocytokines» secreted
by adipose tissue and also by epithelial tissue of breast tumour.
The interplay between IL-1 family cytokines and leptin has been
well documented in metabolic diseases and obesity and not in hu-
man breast cancer.
In this minireview, we clearly demonstrate an important role for
the IL-1 family members and other adipocytokines in breast cancerth the risk (susceptibility) and prognosis of breast cancer. BC: breast cancer; CL: breast
lar carcinoma; DCIS: ductal carcinoma in situ.
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Fig. 1. Proposed model outlining the possible signaling pathways involved between IL-1 family members and other adipocytokines in breast cancer progression.
Adipocytokines are produced by mammary adipocytes (leptin, adiponectin, and resistin) or inﬂammatory cells inﬁltrating fat (IL-1 family members, resistin) where they
cross-regulate [71,82,89]. IL-1 is released from adipose tissue and can regulate in a paracrine manner the other adipocytokines involved in adipocyte-epithelial interactions
[74,89]. Leptin and IL-1 act directly on mammary epithelial cells to enhance aromatase production [40,59] and promote tumour growth, migration and invasion in breast
cancer [10–11,39–40,48–51]. In contrast, IL-1ra and adiponectin exert a direct growth inhibitory effect on breast cancer cells [11,79,80]. Mammary epithelial tumour cells
produce a high amount of adipocytokines [11,13,54,78] and leptin may interplay with IL-1 family members to mediate the secretion of epithelial-derived proteins [90]. In the
tumour microenvironment, IL-1 has local effects on stromal or inﬁltrating cells that result in production of leptin [19] and other tumour growth mediators [14,15] responsible
for breast cancer progression.
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(Table 1). In particular, IL-1 and leptinmay represent a set of biolog-
ical predictors for disease course in breast cancer. Based on these
observations, we have constructed a hypothetical model describing
the role of adipocytokines within the breast cancer microenviron-
ment. In this model (Fig. 1), we hypothesize that mammary adipose
cells express both agonists (IL-1, leptin) and antagonists (IL-1ra,
adiponectin). These adipocytokines then act in both an autocrine
and paracrinemanner via their receptors onmammary tumour cells
to (a) inﬂuence tumour cell proliferation, migration and invasion in
breast cancer; (b) regulate the production of epithelial-derived pro-
teins, angiogenic proteins and growth factors; (c) stimulate other
cells in the tumour microenvironment to invade and proliferate.
Since mammary glandular epithelium interacts with interstitial
cells during the development of breast cancer, further studies will
be necessary to clarify the interplay between the different adipocy-
tokines (leptin, adiponectin, resistin, IL-1) in the different compart-
ments involved: epithelium, inﬂammatory cells, adipose tissue and
myoepithelial tissue which has been called ‘‘natural tumour sup-
pressor” due partly to its ability to inhibit the proliferation of
breast carcinoma cells [86].
Because fat increase is associated with estrogen bioavailability
and breast cancer risk, IL-1 family members may be included withother adipocytokines as indicators of breast cancer assessment. In
addition, the clinical approach may help to assess the inﬂuence of
cytokines in the process of breast carcinogenesis in patients
according to their diet, nutrition status (lean phenotype, obesity)
and to determine the potential diagnosis/prognosis impact of these
molecules and their receptors, in order to develop efﬁcient strate-
gies of prevention and molecules with therapeutic beneﬁts. In par-
ticular, if it was proven that IL-1ra is able to reduce excessive
production of IL-1 and leptin in breast adipose tissue, recombinant
IL-1ra currently used as a therapeutic molecule in rheumatoid
arthritis [28] could represent an alternative chemotherapy in
breast cancer by targeting adipose tumour site with lipidic micro-
encapsulated cells secreting human IL-1ra, as successfully tested in
ﬁbrosarcoma [32].
Since adipose tissue from obese patients overexpresses several
adipocytokines, some authors have suggested that adipose mass
reduction after weight loss may help restore inﬂammatory levels
by decreasing the adipose mRNA expression and secretion of pro-
inﬂammatory adipocytokines. In fact, the loss of body mass is
accompanied with a decrease in serum leptin levels [87]. It is also
intriguing that in patients with morbid obesity, which is a
well-known risk factor of post-menopausal breast cancer, serum
levels of IL-1ra are 7-fold higher as compared to non-obese
264 S. Perrier et al. / FEBS Letters 583 (2009) 259–265patients (1750 vs. 250 pg/ml) and decrease after weight loss from
bypass surgery [88]. IL-1ra concentrations correlate with lean
BMI, the degree of insulin resistance and leptin levels, reﬂecting
IL-1ra production by adipose tissue [12]. In this study, IL-1b and
IL-1ra were detected in human adipose tissue at 6–8 and 8–12 pg/
mg, respectively, and were mainly localized in visceral adipose tis-
sue unlike leptin which was mainly present in subcutaneous adi-
pose tissue. Modulation of adipocyte IL-1ra by IL-1 suggests an
autocrine loop of regulation within adipose tissue [89]. Increased
circulating IL-1ra levels in obese patientsmay have a protective role
in response to high leptin levels and pertain to its immunomodula-
tory and/or metabolic activities as described in sepsis or inﬂamma-
tory disorders [4]. In rheumatoid arthritis, for example, IL-1ra and
leptin are correlated, independently of age and BMI [21].
In conclusion, the fact that adipose leptin and IL-1members’ pro-
duction is up-regulatedwhile adiponectin production is strongly re-
duced in obesity may help to explain why obesity is a risk factor of
developing breast cancers. The study of simultaneous production of
IL-1 familymembers and other adipocytokines in breast cancermay
allow a better understanding to how they are involved in the com-
plex perturbations leading to the dysregulation of tumour cells and
their diagnosis/prognosis impact when associated.Acknowledgements
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